The role of CXCL10 in prognosis of patients with colon cancer and tumor microenvironment remodeling.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
24 Sep 2021
24 Sep 2021
Historique:
received:
21
02
2021
accepted:
26
08
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
6
10
2021
Statut:
ppublish
Résumé
Tumor microenvironment (TME) has gradually emerged as an important research topic in the fight against cancer. The immune system is a major contributing factor in TME, and investigations have revealed that tumors are partially infiltrated with numerous immune cell subsets. We obtained transcriptome RNA-seq data from the the Cancer Genome Atlas databases for 521 patients with colon adenocarcinoma (COAD). ESTIMATE algorithms are then used to estimate the fraction of stromal and immune cells in COAD samples. A total of 1109 stromal-immune score-related differentially expressed genes were identified and used to generate a high-confidence protein-protein interaction network and univariate COX regression analysis. C-X-C motif chemokine 10 (CXCL10) was identified as the core gene by intersection analysis of data from protein-protein interaction network and univariate COX regression analysis. Then, for CXCL10, we performed gene set enrichment analysis, survival analysis and clinical analysis, and we used CIBERSORT algorithms to estimate the proportion of tumor-infiltrating immune cells in COAD samples. We discovered that CXCL10 levels could be effective for predicting the prognosis of COAD patients as well as a clue that the status of TME is transitioning from immunological to metabolic activity, which provided additional information for COAD therapies.
Identifiants
pubmed: 34559115
doi: 10.1097/MD.0000000000027224
pii: 00005792-202109240-00024
pmc: PMC10545341
doi:
Substances chimiques
Biomarkers, Tumor
0
CXCL10 protein, human
0
Chemokine CXCL10
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27224Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
EMBO Rep. 2019 Apr;20(4):
pubmed: 30833345
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Mol Cancer. 2012 Jan 11;11:3
pubmed: 22236567
Endocrinology. 2007 May;148(5):2317-25
pubmed: 17255201
Oncotarget. 2015 Sep 22;6(28):24978-89
pubmed: 26317795
J Cardiovasc Transl Res. 2016 Aug;9(4):302-14
pubmed: 27271043
Blood. 2007 Dec 1;110(12):3827-32
pubmed: 17766680
J Exp Med. 2018 Jun 4;215(6):1693-1708
pubmed: 29769248
Cancer Res. 2012 Jul 1;72(13):3175-86
pubmed: 22562465
Int J Cancer. 2014 Feb 1;134(3):530-41
pubmed: 23873303
Cancer Res. 2018 Jul 15;78(14):3793-3808
pubmed: 29748374
Am J Pathol. 2007 Jul;171(1):32-42
pubmed: 17591951
Breast Cancer Res Treat. 2014 May;145(1):73-82
pubmed: 24715380
Tumour Biol. 2014 Oct;35(10):9683-91
pubmed: 24969558
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Oncotarget. 2014 Nov 30;5(22):11064-80
pubmed: 25415223
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Autoimmun Rev. 2014 Mar;13(3):272-80
pubmed: 24189283
Mol Cell Biol. 2005 Jul;25(14):6247-58
pubmed: 15988033
Clin Cancer Res. 2013 Jan 15;19(2):336-46
pubmed: 23213058
Circ Res. 2015 Feb 27;116(5):876-83
pubmed: 25605650
Blood. 2016 Jun 16;127(24):3082-91
pubmed: 27020088
Eur J Immunol. 2007 Feb;37(2):338-50
pubmed: 17274000
Am J Pathol. 2018 Aug;188(8):1921-1933
pubmed: 30029779
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Commun. 2013;4:2612
pubmed: 24113773
Cancer Immunol Immunother. 2015 Feb;64(2):225-35
pubmed: 25344904